within Pharmacolibrary.Drugs.ATC.L;

model L01XY01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 100 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cytarabine and daunorubicin is a combination chemotherapy regimen commonly used in the treatment of acute myeloid leukemia (AML). Cytarabine is an antimetabolite, and daunorubicin is an anthracycline; both act to inhibit cancer cell growth. The combination is a standard induction treatment in AML and is approved and widely used.</p><h4>Pharmacokinetics</h4><p>No specific published pharmacokinetic data for the fixed combination of cytarabine and daunorubicin (L01XY01) exist. The following parameters are estimates based on the known pharmacokinetics of the individual drugs in adult patients with AML, administered intravenously.</p><h4>References</h4><ol><li><p>Li, S, et al., &amp; Song, PY (2022). Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1200 123275–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2022.123275&quot;>10.1016/j.jchromb.2022.123275</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35551041/&quot;>https://pubmed.ncbi.nlm.nih.gov/35551041</a></p></li><li><p>Mayer, LD, et al., &amp; Louie, AC (2019). CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. <i>International journal of nanomedicine</i> 14 3819–3830. DOI:<a href=&quot;https://doi.org/10.2147/IJN.S139450&quot;>10.2147/IJN.S139450</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31213803/&quot;>https://pubmed.ncbi.nlm.nih.gov/31213803</a></p></li><li><p>Bayne, WF, et al., &amp; Swenson, CE (2009). Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. <i>Journal of pharmaceutical sciences</i> 98(7) 2540–2548. DOI:<a href=&quot;https://doi.org/10.1002/jps.21620&quot;>10.1002/jps.21620</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19009594/&quot;>https://pubmed.ncbi.nlm.nih.gov/19009594</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XY01;
